Advertisement
Advertisement

JBIO

J

Jade Biosciences, Inc. Common Stock

15.60
USD
Sponsored
+0.22
+1.41%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

15.61

+0.01
+0.05%

JBIO Earnings Reports

Positive Surprise Ratio

JBIO beat 6 of 18 last estimates.

33%

Next Report

Date of Next Report
Mar 23, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.50
Implied change from Q3 25 (Revenue/ EPS)
--
/
+4.17%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-92.48%

Jade Biosciences, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, JBIO reported earnings of -0.48 USD per share (EPS) for Q3 25, beating the estimate of -0.68 USD, resulting in a 30.18% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +10.54% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.50 USD, with revenue projected to reach -- USD, implying an increase of 4.17% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Jade Biosciences, Inc. Common Stock reported EPS of -$0.48, beating estimates by 30.18%, and revenue of $0.00, 0% as expectations.
The stock price moved up 10.54%, changed from $9.68 before the earnings release to $10.70 the day after.
The next earning report is scheduled for Mar 23, 2026.
Based on 9 analysts, Jade Biosciences, Inc. Common Stock is expected to report EPS of -$0.50 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement